CHARLOTTE, N.C., Jan. 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 7:30 am PT (10:30 am ET). As part of the conference, the Company is providing an update on its 2023 full year anticipated financial results, with net sales expected to be at or above the high end of the Company's previously provided outlook range of $3.90 billion to $3.94 billion. For th ...

Third Quarter 2023 Earnings Conference Call Dentsply Sirona November 2, 2023 Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this presentation. The Company's forward-looking statements represen ...

DENTSPLY SIRONA, Inc. (NASDAQ:XRAY) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Andrea Daley - VP, IR Simon Campion - CEO, President & Director Glenn Coleman - EVP & CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Kevin Caliendo - UBS Jason Bednar - Piper Sandler & Co. Jeffrey Johnson - Robert W. Baird & Co. Jonathan Block - Stifel, Nicolaus & Company Operator Good day, and thank you for standing by. Welcome to the Dentsply Sirona Third Quarter 2023 E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) Delaware 39-1434669 13320 Ballantyne Corporate Place, Char ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

DENTSPLY SIRONA, Inc. (NASDAQ:XRAY) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Andrea Daley - Vice President, Investor Relations Simon Campion - President and Chief Executive Officer Glenn Coleman - Executive Vice President, Chief Financial Officer Andreas Frank - Executive Vice President, Chief Business Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Bank of America Jeff Johnson - Baird Kevin Caliendo - UBS Jonathan Block - Stifel ...

Second Quarter 2023 Earnings Conference Call August 3, 2023 Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this presentation. The Company's forward-looking statements represent current expecta ...

DENTSPLY SIRONA, Inc. (NASDAQ:XRAY) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants Andrea Daley - VP, IR Simon Campion - CEO, President & Director Glenn Coleman - EVP & CFO Andreas Frank - EVP & Chief Business Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Jeffrey Johnson - Robert W. Baird & Co. Erin Wright - Morgan Stanley Daniel Clark - Bank of America Merrill Lynch Brandon Vazquez - William Blair & Company Jonathan Block - Stifel, Nicolaus & Company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

Revenue and Sales Performance - For the year ended December 31, 2022, Technologies & Equipment (T&E) net revenues represented approximately 59.1% of worldwide net revenues, while Consumables net revenues accounted for 40.9%[19]. - The net sales for each product category as a percentage of the Company's total net sales for the year ended December 31, 2022, were: Equipment & Instruments 17.3%, Implants 14.5%, CAD/CAM 12.8%, Orthodontics 7.6%, Healthcare 6.9%, Endodontic & Restorative 29.8%, and Other consumables 11.1%[29]. - Net sales for DENTSPLY SIRONA Inc. decreased by 7.3% year-over-year, with an organic sales decline of 0.5% for the year ended December 31, 2022[200]. - The company reported a net loss of $950 million for 2022, compared to a net income of $411 million in the previous year, primarily due to a goodwill impairment charge of $1,187 million[200]. - Cash from operations was $517 million, down from $657 million in the prior year[200]. - Sales in China declined by $93 million during 2022 relative to 2021 due to COVID-19 restrictions and reduced patient traffic[206]. - Approximately 3% of consolidated net sales came from Russia and Ukraine, with net assets in these countries totaling $83 million as of December 31, 2022[206]. Product Innovation and Development - Dentsply Sirona's new product innovations accounted for approximately 14% of 2022 sales, highlighting the company's commitment to continuous product development[38]. - The company unveiled its cloud solution DS Core in 2022, developed in collaboration with Google Cloud, to integrate digital dentistry workflows across its devices and services[37]. - Dentsply Sirona's R&D investments focus on accelerating product and clinical innovation, with an objective to achieve more frequent development and release cycles[39]. - The Company invests at least 4% of annual net sales in R&D, focusing on innovation and digital technology[41]. - The company identified new products as a critical part of its growth opportunities, but faces risks of product obsolescence due to rapid technological advancements[101]. - Dentsply Sirona's Orthodontics product category includes the SureSmile aligner solution and the Byte direct-to-consumer aligner solution, reflecting its focus on innovative treatment options[25]. Market Presence and Strategic Acquisitions - The company has a significant market presence in over 150 countries, with a strong foothold in Europe and the Asia-Pacific region[20]. - Dentsply Sirona has made strategic acquisitions, including the purchase of Datum Dental for OSSIX bone regenerative collagen and Propel for VPro aligner treatment devices, to enhance its product offerings[38]. - The Company completed several acquisitions in 2021, including Datum Dental and Propel, to enhance its product offerings and market position[43]. - Byte, a leading provider in the direct-to-consumer aligner market, was acquired on December 31, 2020, expanding the company's market presence[159]. Operational Efficiency and Challenges - The Company aims to leverage its global scale to improve operational efficiencies across procurement, logistics, and manufacturing[40]. - The company is undergoing organizational restructuring to enhance profitability and operational performance, which may involve significant costs and risks[113]. - The company has implemented strategic procurement initiatives to leverage alternative sources of raw materials and transportation[211]. - The company faces risks related to obtaining necessary product approvals and marketing clearances from regulatory authorities like the FDA[144]. - The company relies on a limited number of suppliers for key products, which poses risks of supply chain disruptions and manufacturing delays[103]. Financial and Regulatory Risks - The company identified material weaknesses in internal control over financial reporting, which could impact the accuracy and timeliness of financial results[78]. - The company restated certain previously issued consolidated financial statements, which may affect investor confidence and incur unanticipated costs[78]. - The company is subject to ongoing SEC investigations and several securities class action lawsuits, which could harm its business and financial condition[87]. - The company faces risks from litigation and claims, including potential securities class actions and product liability, which could harm its business and cash flows[171]. - The company is exposed to evolving privacy and data protection regulations, such as the GDPR, which could result in significant fines and compliance challenges[100]. Employee and Corporate Responsibility - The Company employs over 15,000 employees worldwide, with a focus on attracting and retaining talent through diverse programs[59]. - The company aims to achieve global gender pay equity and gender parity by 2025, as part of its sustainability program[64]. - As of December 31, 2022, the company established seven employee resource groups with approximately 2,000 members globally, focusing on talent development and employee engagement[66]. - The company is committed to sustainable operations, investing in employees, customers, and the environment[40]. - The company has a dedicated Employee Health & Safety program aligned with international standards, ensuring employee safety and well-being[70]. Economic and Market Conditions - The company is exposed to risks from changes in global economic conditions, including inflation and supply chain shortages[84]. - The impact of inflation and rising interest rates has pressured customer financing for equipment purchases, affecting sales volumes[210]. - Changes in foreign exchange rates may adversely impact the company's consolidated financial statements, as approximately two-thirds of sales are outside the U.S.[139]. - The company faces challenges related to reimbursement levels from third-party payors, which could lead to revenue declines[150]. - The ongoing COVID-19 pandemic has negatively impacted business operations, particularly in China, leading to distribution constraints and reduced patient traffic[164]. Environmental and Social Governance - The company is committed to diversity, equity, and inclusion, with a strategy focused on embedding these values into its culture[63]. - Expectations regarding environmental, social, and governance considerations may lead to potential liabilities and increased costs for the company[176]. - Climate change and natural disasters pose risks to the company's operations, potentially disrupting production and distribution across its global facilities[174].